Early Breast Cancer News

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Addition of Everolimus to Endocrine Therapy Did Not Improve Survival, Increased Toxicity Among Patients With High-Risk HR-Positive Early-Stage Breast Cancer

07/17/2024

Stephanie Holland ;

Results from the SWOG S127 study demonstrated that the addition of everolimus to endocrine therapy did not improve survival outcomes among patients with high-risk, HR-positive, early-stage breast cancer.

Results from the SWOG S127 study...

07/17/2024

Oncology

News

Trastuzumab Emtansine Improved Long-Term Outcomes Among Patients With HER2-Positive Early Breast Cancer

07/08/2024

Stephanie Holland ;

Long-term results from the phase 2 ATEMPT trial demonstrated that adjuvant trastuzumab emtansine improved long-term outcomes among patients with HER2-positive early-stage breast cancer.

Long-term results from the phase...

07/08/2024

Oncology

Conference Coverage

Addition of Carboplatin to Anthracycline and Taxane Therapy Improved Event-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer

06/17/2024

Stephanie Holland

According to results from the phase 3 PEARLY trial, the addition of carboplatin to standard anthracycline and taxane therapy significantly improved event-free survival among patients with early-stage triple-negative breast cancer.

According to results from the...

06/17/2024

Oncology

News

Ribociclib Added to Endocrine Therapy Improved Disease-Free Survival Among Patients With HR-Positive, HER2-Negative Early Breast Cancer

04/04/2024

Stephanie Holland

According to interim results from an international phase 3 trial, ribociclib plus either letrozole or anastrozole significantly improved disease-free survival among patients with HR-positive, HER2-negative early breast cancer.

According to interim results...

04/04/2024

Oncology

News

Fulvestrant Did Not Significantly Improve Response Rate Compared to Anastrozole in ER-Positive, HER2-Negative Early Breast Cancer

02/09/2024

Stephanie Holland

Results from a phase 3 trial found fulvestrant with or without anastrozole did not significantly improve 6-month endocrine-sensitive disease rate compared to anastrozole alone among postmenopausal patients with ER-positive, HER2-negative,...

Results from a phase 3 trial...

02/09/2024

Oncology

News

Trastuzumab Emtansine Improved Survival Among Patients With Residual Invasive HER2-Positive Early Breast Cancer

12/08/2023

Allison Casey

According to results from the KATHERINE trial, trastuzumab emtansine improved the invasive disease-free survival and overall survival among patients with residual invasive HER2-positive early breast cancer when compared with trastuzumab.

According to results from the...

12/08/2023

Oncology

News

Omission of Sentinel Lymph Node Biopsy Safe For Patients With Early Breast Cancer With Negative Ultrasonography of Axillary Lymph Nodes

11/29/2023

Stephanie Holland

According to results from the phase 3 SOUND study, omitting sentinel lymph node biopsy is safe for patients with early breast cancer who have negative results on ultrasonography of the axillary lymph node when the lack of pathological...

According to results from the...

11/29/2023

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology